Indian court refuses injunction in Merck's Januvia/Janumet case
This article was originally published in Scrip
Executive Summary
The Delhi High Court in India has refused to grant an injunction against Glenmark in a case concerning the Indian firm's recent launch in India of generic versions of Merck's diabetes therapies, Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride).